Mar 03–06, 2024 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Stefano Romeo, Michael Charlton, Silvia C. Sookoian, and Gregory Tesz

-
Scientific Organizers: Stefano Romeo, Michael Charlton, Silvia C. Sookoian, and Gregory Tesz
Stefano Romeo
Michael Charlton
Silvia C. Sookoian
Gregory Tesz
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Booking Function
Fundraising
Sunday, March 3, 2024
Monday, March 4, 2024
MASH and Fibrosis: What have we Learned from Clinical Trials?
Nutritional, Non-Alcoholic or Metabolic associated Fatty Liver Disease?
Worsening of Metabolic Fluxes: From Hepatic Steatosis to MASH
MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics
Aging Promotes Metabolic Dysfunction-associated Steatotic Liver Disease by Inducing Ferroptotic Stress in Hepatocytes
Characterization and Purification of Hypertrophied Hepatic Stellate Cells and their Association with Liver Fibrosis
Activation of Hepatocyte E4BP4-OPN Axis Promotes Liver Fibrosis in Non-alcoholic Steatohepatitis
Glucolipotoxicity Regulates the Secretion of Interleukin-6 Trans-Signaling Inhibitor, sgp130, Through Matrix Metalloproteases Shedding in Hepatic Stellate Cells
Glucose-mediated Control of STAT3 Activation in Fibrosis
Targeting the Endocrine Actions of a MASH-inducible Hepatic Stellate Cell Secreted Protein – a Worthwhile Venture
Interrogating the Effect of Fibrosis on Hepatocyte Transcriptome and Lipid Accumulation Phenotype
Lean NAFLD: Molecular Mechanisms of MASH and Fibrosis
Molecular Basis of Ethnic Differences in MASH and Fibrosis
MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics
Cirrhotic and Noncirrhotic: Mechanisms of Hepatocellular Carcinoma in SLD
Short Talk: Short Talk: A Data-Driven Cluster Analysis Identifies Distinct Types of Metabolic Dysfunction-Associated Steatotic Liver Disease
Tuesday, March 5, 2024
Precision Slice Cut as a Preclinical Model of MASH
Modeling MASH in Mice: Overcoming Problems in Translation
Short Talk: Short Talk: PNPLA3 p.I148M Variant Affects Lipid Droplets Number and Size in Patient-derived Liver Organoids
Short Talk: Short Talk: Characterizing 99 Cardiometabolic Candidate Genes for a Role in MASLD Using CRISPR/Cas9, in vivo Imaging and Deep Learning in Zebrafish Larvae
Short Talk: Short Talk: Non-Invasive in vivo Imaging of Liver Spheroids Engrafted in the Anterior Chamber of the Eye
Short Talk: Short Talk: Using siRNA Generated Isogenic Pairs in a Micropatterned Primary Hepatocyte Co-culture (HEPATOPAC) to Define the Role of CIDEB in a Model of Hepatic Steatosis
Professor
Staff Scientist
Identifying Populations at Risk for Liver Events – is MASH with Fibrosis by Histology the only Way?
Is Regression of Fibrosis the Only Surrogate for Outcomes Benefit?
Assessing Response to Drug Treatment Beyond Liver Biopsy
Short Talk: Short Talk: Resolution of MASH with No Worsening of Fibrosis after Bariatric Surgery Improves 15-year Survival
Wednesday, March 6, 2024
Human Genetics of Steatotic Liver Disease: What Have We Learned So Far?
PNPLA3, Estrogens and SLD Progression in Women
Human Genetics of Liver Disease and Implications for Therapeutic Development
Short Talk: Short Talk: Association of a Glucagon-like Peptide-1 Receptor Gene Variant with Metabolic Dysfunction Associated Liver Disease (MASLD)
Short Talk: Short Talk: Overexpressing PNPLA3-148I or ABHD5 Differentially Protects Primary Human Hepatocytes from Hypercaloric Diet-induced Steatosis Depending on their PNPLA3 Genotype
Short Talk: Short Talk: Hsd17b13 Loss Adversely Impacts Glucose-insulin Metabolism
Short Talk: Short Talk: Murine HSD17B13 Does Not Control Liver Steatosis and Modestly Impacts Fibrosis Under Specific Dietary Conditions
Development of Liver-targeted Interleukin-22 for Metabolic Dysfunction Associated Steatohepatitis
Efruxifermin Significantly Improved Collagen Biomarkers Consistent with Beneficial ECM Remodeling in Patients with F2-F3 Fibrosis Due to MASH
The Postprandial Plasma Proteome is Altered in People with Metabolic Dysfunction-associated Steatotic Liver Disease
A Novel Humanized Model of NASH and its Treatment with META4 a Potent Agonist of MET
EphA2 Promotes Inflammation and Alters Hepatocyte Metabolism to Enhance Metabolic Dysfunction-associated Steatotic Liver Disease
Methionine Aminopeptidase 2 (MetAP2) Regulates Anabolic and Catabolic Metabolism in Hepatocytes Through Ancient Mechanisms That Control Protein Translation
Investigating MASLD Using a Multi-level Computational Model
TMEM55B deficiency alters lysosomal fatty acid trafficking and induces metabolic dysfunction associated steatohepatitis (MASH)
HSD17B13 Inhibition with INI-822 Phenocopies the Human HSD17B13 Protective Allele
Targeting PNPLA3 148M to Treat MASH and Fibrosis
Hepatic Stellate Cell Plasticity and Maladaptive Fibrogenic Memory in CLD
Thursday, March 7, 2024
Subscribe for Updates